The vascular endothelial growth factor (VEGF) pathway has been recognized as a key
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …

Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …

Since the discovery of the RET receptor tyrosine kinase in 1985, alterations of this protein
have been found in diverse thyroid cancer subtypes. RET gene rearrangements are …

Angiogenesis is the process of formation of new blood vessels from existing ones. Vessels
serve the purpose of providing oxygen, nutrients and removal of waste from the cells. The …

Targeted therapies by means of compounds that inhibit a specific target molecule represent
a new perspective in the treatment of cancer. In contrast to conventional chemotherapy …

Background Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during …

Thyroid cancer is the most common malignant tumor of the endocrine system. The most
frequent type of thyroid malignancy is papillary carcinoma. These tumors frequently have …

The development and use of antiangiogenesis agents, particularly those targeting vascular
endothelial growth factor (VEGF), has become an integral component of anticancer …

There are four members of the EGFR family: EGFR, erbB2, erbB3 and erbB4. These
receptors form ligand-activated oligomers which regulate intracellular processes via an …

Thyroid cancer is the most common malignant tumor of the endocrine system and accounts
for approximately 1% of all newly diagnosed cancer cases. The most frequent type of thyroid …